The antibacterial activity of silver nanoparticles with a size of 43.6 ± 10.7 nm against strain Mycobacterium tuberculosis H37Rv was studied in vitro (the studied concentrations of silver nanoparticles were 0.1; 1; 10; 25, and 50 μg/mL) and in an experimental murine model of chronic tuberculosis. It was shown that silver nanoparticles at a concentration of 50 μg/mL suppress mycobacterial growth in vitro by 2 times. The administration of silver nanoparticles via inhalation at a dose of 0.1 mg/kg to tuberculosis-infected mice resulted in a twofold decrease in the colonization of the lungs and spleens by M. tuberculosis. In these animals, the quantity of protein in the broncho-pulmonary lavage fluid was reduced by two times, to 1908.5 ± 105.7 (P < 0.001), which indicates a decrease in the inflammatory processes in the lungs. The level of the production of reactive oxygen species by neutrophils increased, reflecting their bactericidal potential, which was reduced by 2.7 times before treatment as compared to the control group of animals (P < 0.001). After the introduction of silver nanoparticles, a recovery in the ratio of lymphocyte populations in the spleen and cytokine balance was observed. It was expressed by a decrease in the levels of IFN-γ, TNF-α, and IL-4 in the blood serum and broncho-pulmonary lavage fluid in TB mice. Thus, it was shown for the first time that the inhalation of silver nanoparticles stabilized with polyvinylpyrrolidone led not only to a noticeable bactericidal effect but also recovered the balance of the immune system of mice.
In this study we have identified the influence of Argovit on the immune system of mice after inhalation or intragastric or subcutaneous administration. Argovit is a preparation of polyvinylpyrrolidone-coated (43.6 ± 10.7 nm) silver nanoparticles. We have found no toxic effect on the immune cells and organs, changes in T- and B-lymphocytes quantity in the spleen, or proinflammatory cytokine production after exposure to silver nanoparticles through inhalation or intragastrically. The subcutaneous administration of silver nanoparticles has changed the ratio of lymphocyte subpopulations, increased the quantity of IFN-γ-producing T-lymphocytes 3.6-fold compared with the control, and increased the content of IFN-γ in the serum of mice to 125 ± 9.2 pg/mL compared to the control (74.5 ± 6.4 pg/mL).
22 October 2020 in Problems of Particularly Dangerous Infections
Francisella tularensis is an intracellular bacterium that causes tularemia. Progress in creating a safe and effective vaccine for the prevention of tularemia is challenging due to a lack of knowledge about immunological parameters indicative of protective adaptive immunity. Objective of the research was to assess the effect of modifications of the F. tularensis 15 NIIEG genome on the immunogenic and protective properties of F. tularensis 15/23-1ΔrecA and F. tularensis 15/23-1/sodBΔrecA strains. Materials and methods. Multi-parameter flow cytometry and the measurement of secreted cytokines were used to characterize the responses of mouse spleen lymphocytes in response to re-stimulation of F. tularensis with acid-insoluble complex (AIC) in vitro. Also, the titers of specific antibodies to F. tularensis lipopolysaccharide in blood serum were analyzed by enzyme-linked immunosorbent assay. Results and discussion. It has been shown that immunization with the studied strains led to a significant increase in CD4+ and/or CD8+ T cells capable of expressing functional markers: CD69, CD25 and/or CD28; an increase in the subpopulation of T-helpers synthesizing IFN-γ. In the body of immune mice, a pool of B-lymphocytes was formed, capable of secreting IFN-γ in response to their stimulation with AIC. Immunization with the strain 15/23-1/sodBΔrecA provided 70% protection in mice from intranasal infection with a virulent strain of F. tularensis SchuS4. More pronounced protective properties were associated with the activation of not only B-lymphocytes and T-helpers, but also with the simultaneous activation of cytotoxic T-lymphocytes.
Bacillus anthracis has three main virulence factors: an extracellular capsule and two binary toxins (lethal toxin—consists of a lethal factor and a protective antigen, and edema toxin—consists of an edema factor and a protective antigen). In the Russian Federation, the epidemiological situation regarding anthrax infection remains unfavorable. In the late stages of an anthrax infection, antibiotic therapy becomes ineffective and the patient dies within 24 h as a large amount of lethal toxin accumulates in the patient’s blood. Antibodies capable of neutralising lethal toxin (LT) can be an effective treatment for these patients. The objective of the study was to construct a chimeric monoclonal antibody targeting the protective antigen of the LT and to elucidate its mechanism of toxin neutralization. In this work, a chimeric monoclonal antibody (xi1E10) directed against the protective antigen was successfully produced. Both in vitro and in vivo experiments demonstrated the capacity of xi1E10 to neutralize lethal toxin. Confocal microscopy revealed that xi1E10 effectively suppresses the formation of a functional pore, thereby blocking the translocation of the lethal factor into the cytosol. These findings indicate that the monoclonal antibody xi1E10 represents a promising candidate for the development of a therapeutic drug.